Merck’s much ballyhooed new pill treatment Molnupiravir to fight the wuhan, according to Merck, works well in wuhan virus infected people having blood oxygen levels above 93%, while Aurobindo and MSN testing labs of India say the drug does no good in patients having under 93% blood oxygen levels, which translates to Merck’s pill treatment (supposedly) successful in slightly infected people 50% of the time, stacking up poorly against Ivermectin and Hydroxychloroquine, inexpensive drugs up to 90% effective even at the lower blood oxygen levels of hospitalized people.
All Material Copyright The Right Sway 2022
